Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for
the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that
involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other
nonsteroidal anti-inflammatory drugs.